Department of Health Care Policy, Harvard Medical School, Boston, MA
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Diabetes Care. 2018 Aug;41(8):1776-1782. doi: 10.2337/dc17-2585. Epub 2018 May 24.
Prompt initiation and intensification of antidiabetic therapy can delay or prevent complications from diabetes. We sought to understand the rates of and factors associated with the initiation and intensification of antidiabetic therapy among commercially insured patients in the U.S.
Using 2008-2015 commercial claims linked with laboratory and pharmacy data, we created an initiation cohort with no prior antidiabetic drug use and an HbA ≥8% (64 mmol/mol) and an intensification cohort of patients with an HbA ≥8% (64 mmol/mol) who were on a stable dose of one noninsulin diabetes drug. Using multivariable logistic regression, we determined the rates of and factors associated with initiation and intensification. In addition, we determined the percent of variation in treatment patterns explained by measurable patient factors.
In the initiation cohort ( = 9,799), 63% of patients received an antidiabetic drug within 6 months of the elevated HbA test. In the intensification cohort ( = 10,941), 82% had their existing antidiabetic therapy intensified within 6 months of the elevated HbA test. Higher HbA levels, lower generic drug copayments, and more frequent office visits were associated with higher rates of both initiation and intensification. Better patient adherence prior to the elevated HbA level, existing therapy with a second-generation antidiabetic drug, and lower doses of existing therapy were also associated with intensification. Patient factors explained 7.96% of the variation in initiation and 7.35% of the variation in intensification.
Approximately two-thirds of patients were newly initiated on antidiabetic therapy, and four-fifths of those already receiving antidiabetic therapy had it intensified within 6 months of an elevated HbA in a commercially insured population. Patient factors explain 7-8% of the variation in diabetes treatment patterns.
及时启动并强化降糖治疗可延缓或预防糖尿病并发症。本研究旨在了解美国商业保险患者启动和强化降糖治疗的比例及其相关影响因素。
我们利用 2008 年至 2015 年的商业索赔数据,与实验室和药房数据进行关联,创建了一个起始队列,纳入既往无降糖药物治疗史且糖化血红蛋白(HbA )≥8%(64mmol/mol)的患者;同时创建了一个强化队列,纳入 HbA 水平≥8%(64mmol/mol)且正在使用一种稳定剂量的非胰岛素类降糖药物的患者。采用多变量逻辑回归分析,确定启动和强化治疗的比例及其相关影响因素。此外,我们还确定了可测量患者因素对治疗模式变化的解释程度。
在起始队列(n=9799)中,63%的患者在 HbA 升高检测后 6 个月内接受了降糖药物治疗。在强化队列(n=10941)中,82%的患者在 HbA 升高检测后 6 个月内强化了现有降糖治疗。HbA 水平越高、通用药物自付比例越低、就诊次数越频繁,与启动和强化治疗的比例越高相关。HbA 水平升高前患者的药物依从性更好、现有治疗药物为第二代降糖药、以及现有治疗药物剂量更低,与强化治疗相关。患者因素解释了起始治疗的 7.96%和强化治疗的 7.35%的变异性。
约有 2/3的患者新开始接受降糖治疗,在商业保险人群中,HbA 升高后 6 个月内,已有降糖治疗的患者中约有 4/5的患者强化了治疗。患者因素解释了 7-8%的糖尿病治疗模式的变异性。